Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Show Lot-to-lot Consistency of Hib-MenAC Mixed With Tritanrix-HBV, Its Non-inferiority to Tritanrix-HBV/Hiberix With or Without Meningitec™, and MenA Response in 2, 4, 6 Month Infants With Hepatitis B Birth Dose

Next Previous
X
Search
Trial Profile

Study to Show Lot-to-lot Consistency of Hib-MenAC Mixed With Tritanrix-HBV, Its Non-inferiority to Tritanrix-HBV/Hiberix With or Without Meningitec™, and MenA Response in 2, 4, 6 Month Infants With Hepatitis B Birth Dose

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-DTP-hepatitis B-meningococcal vaccine groups A and C conjugate (Primary) ; DTP-hepatitis B vaccine; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal infections; Neisseria infections; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 31 Mar 2011 Added actual start and end dates, as reported by Clinicaltrials.gov.
    • 15 Feb 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top